#Hugel #Malaysia #Letybo #Venusys Medical #Kuantan

Introduction

Hugel Inc., a prominent entity in the global medical aesthetics field, has officially launched its botulinum toxin product named Letybo in Malaysia. This launch represents a meaningful milestone as Malaysia emerges as a vital market for medical aesthetics within Southeast Asia.

Event Overview

The introduction of Letybo took place during the prestigious Aesthetic Medicine Surgery Conference Exhibition (AMSC), the largest medical aesthetics gathering in Malaysia, held on August 6-7. Venusys Medical Sdn Bhd, Hugel's local partner, played a key role in presenting Letybo at this significant event. Prominent within the industry, Konstantin Frank, a key opinion leader for Letybo in Europe, shared insights into achieving precise treatment outcomes during his presentation, along with effective clinical strategies.

Hands-On Workshops

Following the conference, a brand launch event and a hands-on workshop were organized on August 8 at The Zenith Hotel Kuantan. Approximately 100 medical professionals attended this workshop, emphasizing training in botulinum toxin injection techniques that blend anatomical knowledge with clinical practices. This approach aims to empower local practitioners and elevate treatment standards in the region.

Strategic Partnership

Venusys Medical, with its headquarters in Malaysia, is recognized for distributing medical aesthetic products and fostering long-standing partnerships with global brands. Hugel's commitment to enhancing local medical expertise is evident as they collaborate with Venusys to deliver specialized training programs tailored to Malaysian professionals. A Hugel representative mentioned their ongoing efforts to improve customer experiences with their premium toxin brand while also accelerating market penetration throughout the region.

About Hugel Inc.

Founded in 2001, Hugel has positioned itself as a leader in the medical aesthetics sector. The company specializes in manufacturing injectables for skin rejuvenation, including botulinum toxin, hyaluronic acid fillers, and skin boosters, alongside absorbable sutures and various cosmetic products. As a leading force in injectable aesthetics within South Korea, Hugel stands unique as the only South Korean company to have received regulatory approvals from the three largest botulinum toxin markets: the United States, China, and Europe.

Commitment to Quality

With a robust commitment to safety and quality, Hugel strives to advance the aesthetics industry through extensive medical affairs, comprehensive training, and active engagement in industry discussions. Building upon two decades of experience, Hugel has established a presence in around 70 countries and has nine global subsidiaries in the US, Australia, Canada, Taiwan, China, Hong Kong, Singapore, and Thailand. This expansion strategy positions Hugel for continued growth in the global market.

Conclusion

In summary, the launch of Letybo in Malaysia signifies Hugel's strategic initiative to expand its footprint in the Southeast Asian medical aesthetics market. Through its collaboration with Venusys Medical and ongoing training programs, Hugel is poised to reinforce its leading position while contributing to the development of local medical professionals in the region.

For more information, the company's PR team can be contacted via email.